Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group
Aapro, M S × van Wijk, F H van der Burg, M E L ten Bokkel Huinink, W Vergote, Ignace Guastalla, J P Rosso, R Kobierska, A Beex, L V A Namer, M Splinter, T E W Vermorken, J B #
European Journal of Cancer vol:39 issue:8 pages:1141-1143
30 patients with advanced ovarian cancer, all platinum pretreated, were treated with an induction cycle of fotemustine. Maintenance therapy was given to 6 patients. No objective response was observed among the 21 evaluable patients. The main toxicities were gastrointestinal, with grade 3 nausea and vomiting reported in 40% of the patients, and haematological, with grade 4 leucopenia reported in 2 patients and grade 4 thrombocytopenia in 5 patients. Therefore, no role has been demonstrated in our cohort for the use of fotemustine, a nitrosourea, in pretreated ovarian cancer.